Clene to Provide CNM-Au8® ALS Program Update
Clene Inc. (CLNN)
Company Research
Source: GlobeNewswire
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced it plans provide an update on its CNM-Au8 program in ALS, and to host an investor call and webcast at 8:30 am ET on Wednesday, December 3, 2025. The webcast is accessible via the link below or the Investors section of the Company’s website located here. Webcast Information:Title: CNM-Au8 ALS Program Update Presenters: Rob Etherington, CEO and President, Dr. Ben Greenberg, Head of Medical, Michael Hotchkin, Chief Development Officer and a KOLDate: December 3, 2025Start Time: 8:30 a.m. ETWebcast link: https://viavid.webcasts.com/starthere.jsp?ei=1744985&tp_key=9fb9583d33Dial number: 1-877-407-0779 (US) or 1-
Show less
Read more
Impact Snapshot
Event Time:
CLNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLNN alerts
High impacting Clene Inc. news events
Weekly update
A roundup of the hottest topics
CLNN
News
- Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at Benchmark Co..MarketBeat
- Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.MarketBeat
- Clene (NASDAQ:CLNN) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®GlobeNewswire
- Institutions own 17% of Clene Inc. (NASDAQ:CLNN) shares but individual investors control 56% of the company [Yahoo! Finance]Yahoo! Finance
CLNN
Sec Filings
- 12/3/25 - Form 8-K
- 12/3/25 - Form 8-K
- 11/14/25 - Form 4
- CLNN's page on the SEC website